1. Home
  2. NUVL vs LRN Comparison

NUVL vs LRN Comparison

Compare NUVL & LRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$103.39

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Stride Inc.

LRN

Stride Inc.

HOLD

Current Price

$84.10

Market Cap

6.3B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
LRN
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.3B
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
NUVL
LRN
Price
$103.39
$84.10
Analyst Decision
Strong Buy
Buy
Analyst Count
15
4
Target Price
$135.00
$106.75
AVG Volume (30 Days)
581.9K
1.4M
Earning Date
02-26-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9.29
EPS
N/A
6.50
Revenue
N/A
$2,519,167,000.00
Revenue This Year
N/A
$5.47
Revenue Next Year
N/A
$4.81
P/E Ratio
N/A
$12.93
Revenue Growth
N/A
14.86
52 Week Low
$55.54
$60.62
52 Week High
$113.02
$171.17

Technical Indicators

Market Signals
Indicator
NUVL
LRN
Relative Strength Index (RSI) 48.27 78.91
Support Level $100.19 $77.80
Resistance Level $107.51 $92.46
Average True Range (ATR) 4.89 3.08
MACD -0.41 1.71
Stochastic Oscillator 36.14 66.60

Price Performance

Historical Comparison
NUVL
LRN

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About LRN Stride Inc.

Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.

Share on Social Networks: